Gemtuzumab ozogamicin is a monoclonal anti-CD33 antibody used to treat CD33-positive acute myeloid leukemia. Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody that is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. catechesis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles of calicheamicin per mole of antibody. The antibody is specifically directed against the CD33 antigen present on leukemic myeloblasts in most patients with acute myeloid leukemia (AML). By binding to the CD33 antigen on tumors, the cytotoxic agent blocks the growth of cancerous cells and causes cell death.
Marketing approval of gemtuzumab ozogamicin was granted on May 17, 2000, by FDA as a treatment for patients with CD33-positive AML in first relapse who are 60 years of age or older and who are not considered candidates for cytotoxic chemotherapy [rx]. However, it was voluntarily withdrawn from the market in 2010 due to safety concerns, increased patient deaths, and insufficient evidence of clinical benefit during confirmatory trials [rx]. On September 1, 2017, gemtuzumab ozogamicin was again approved for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia but with a lower dosing regimen and a different schedule in combination with chemotherapy or on its own [rx]. It is also indicated for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial treatment (refractory) [rx].
Mechanism of action
Mylotarg is directed against the CD33 antigen expressed by hematopoietic cells. Binding of the anti-CD33 antibody portion of Mylotarg with the CD33 antigen results in the formation of a complex that is internalized. Upon internalization, the calicheamicin derivative is released inside the lysosomes of the myeloid cell. The released calicheamicin derivative binds to DNA in the minor groove resulting in site-specific DNA double-strand breaks via the formation of a p-benzene diradical 4. Eventually, cell death is induced.
Used for the treatment of acute myeloid leukemia (AML), Mylotarg binds to the CD33 antigen, which is expressed on the surface of leukemic cells in more than 80% of patients with AML. The CD33 antigen is not expressed on pluripotent hematopoietic stem cells or nonhematopoietic cells. This gives Mylotarg the selectivity needed to target leukemic cells.
or
Gemtuzumab ozogamicin is a CD33-directed antibody-drug conjugate (ADC). The antibody portion (hP67.6) recognizes human CD33 antigen. The small molecule, N-acetyl gamma calicheamicin, is a cytotoxic agent that is covalently attached to the antibody via a linker. Nonclinical data suggest that the anticancer activity of gemtuzumab ozogamicin is due to the binding of the ADC to CD33-expressing tumor cells, followed by internalization of the ADC-CD33 complex, and the intracellular release of N-acetyl gamma calicheamicin dimethyl hydrazide via hydrolytic cleavage of the linker. Activation of N-acetyl gamma calicheamicin dimethyl hydrazide induces double-strand DNA breaks, subsequently inducing cell cycle arrest and apoptotic cell death.
Indications
- Indicated for the treatment of patients with CD33-positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for other cytotoxic chemotherapy. Indicated for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial treatment (refractory).
- Acute Myeloid Leukemia (AML)
- Refractory Acute Myeloid Leukemia (AML)
- Relapsed Acute Myelogenous Leukemia (AML)
Use in Cancer
Gemtuzumab ozogamicin is approved to treat:
- Acute myeloid leukemia that is CD33 positive.
- It is used in adults and children aged 1 month and older with the newly-diagnosed diseases.
- It is used in adults and children aged 2 years and older whose disease has relapsed or is refractory (does not respond to treatment).
Gemtuzumab ozogamicin is also being studied in the treatment of other types of cancer.
Contraindications
- low amount of magnesium in the blood
- low amount of calcium in the blood
- low amount of potassium in the blood
- decreased blood platelets
- low levels of a type of white blood cell called neutrophils
- abnormal EKG with QT changes from birth
- hepatic veno-occlusive disease, a type of liver disease
- liver problems
- pregnancy
- a patient who is producing milk and breastfeeding
Dosage
Strengths: 4.5 mg
Acute Myeloid Leukemia
Newly diagnosed CD33-positive acute myeloid leukemia (AML):
COMBINATION REGIMEN (therapy consists of 1 induction cycle and 2 consolidation cycles in combination with chemotherapy):
- Induction: 3 mg/m2 (maximum 4.5 mg/dose) IV over 2 hours on Days 1, 4, and 7 in combination with daunorubicin and cytarabine (for patients who require a second induction cycle, gemtuzumab is NOT given during the second induction cycle)
- Consolidation (2 cycles): 3 mg/m2 (maximum 4.5 mg/dose) IV over 2 hours on Day 1 in combination with daunorubicin and cytarabine
Newly diagnosed CD33-positive acute myeloid leukemia (AML):
SINGLE AGENT REGIMEN (MONOTHERAPY) (therapy consists of 1 induction cycle and up to 8 continuation cycles):
- Induction: 6 mg/m2 IV over 2 hours on Day 1 and 3 mg/m2 IV on Day 8
- Continuation: 2 mg/m2 IV over 2 hours on Day 1 every 4 weeks
Relapsed or Refractory CD33-positive AML:
SINGLE-AGENT REGIMEN (MONOTHERAPY):
- 3 mg/m2 (maximum 4.5 mg/dose) IV over 2 hours on Days 1, 4, and 7
- Treatment in the relapsed or refractory setting consists of a single course of gemtuzumab.
- Premedicate with acetaminophen 650 mg orally and diphenhydramine 50 mg orally or IV one hour prior to infusion, and methylprednisolone (or equivalent) 1 mg/kg orally or IV within 30 minutes prior to infusion. Repeat the same dose of methylprednisolone (or equivalent) for any sign of an infusion reaction (e.g., fever, chills, hypotension, dyspnea) during the infusion or within 4 hours of the infusion.
- Monitor vital signs during infusion and for 4 hours following infusion.
- For patients with hyperleukocytosis (leukocyte count greater than or equal to 30 Gi/L), cytoreduction is recommended prior to the administration of this drug.
- For newly diagnosed CD33-positive acute myeloid leukemia (AML)
- For relapsed or refractory CD33-positive AML
Acute Myeloid Leukemia
Newly Diagnosed De Novo CD33-positive AML (Combination Regimen):
ONE MONTH AND OLDER:
- Body surface area (BSA) less than 0.6 m2: 0.1 mg/kg IV over 2 hours
- BSA 0.6 m2 or greater: 0.3 mg/m2 IV over 2 hours
INDUCTION 1:
- For Induction 1, gemtuzumab is given once in combination with standard chemotherapy; no gemtuzumab is given in the second induction cycle.
INTENSIFICATION:
- No gemtuzumab is given in the first or third intensification cycles; for Intensification 2, gemtuzumab is given once in combination with standard chemotherapy; consider the risks and potential benefits before giving gemtuzumab during Intensification 2.
Relapsed or Refractory CD33-positive AML:
SINGLE-AGENT REGIMEN (MONOTHERAPY):
2 YEARS AND OLDER:
3 mg/m2 (maximum 4.5 mg/dose) IV over 2 hours on Days 1, 4, and 7
- Treatment in the relapsed or refractory setting consists of a single course of gemtuzumab.
- Premedicate children 1 month and older with acetaminophen 15 mg/kg (maximum of 650 mg) orally and diphenhydramine 1 mg/kg (maximum of 50 mg) orally or IV within 1 hour of infusion, and methylprednisolone 1 mg/kg orally or IV within 30 minutes of infusion. Additional doses of acetaminophen and diphenhydramine may be administered every 4 hours if needed. Repeat with the same dose of methylprednisolone (or equivalent) for an infusion reaction (e.g., fever, chills, hypotension, dyspnea) during the infusion or within 4 hours of the infusion.
- Monitor vital signs during infusion and for 4 hours following infusion.
- For patients with hyperleukocytosis (leukocyte count greater than or equal to 30 Gi/L), cytoreduction is recommended prior to the administration of this drug.
- For the treatment of newly diagnosed CD33-positive acute myeloid leukemia in pediatric patients 1 month and older
- For relapsed or refractory CD33-positive acute myeloid leukemia (AML) in pediatric patients 2 years and older
Dose Adjustments
FOR PATIENTS RECEIVING GEMTUZUMAB IN COMBINATION THERAPY:
PERSISTENT THROMBOCYTOPENIA:
- ADULTS: If platelet count does not recover to greater than or equal to 100 Gi/L within 14 days following the planned start date of the consolidation cycle (14 days after hematologic recovery following the previous cycle), discontinue gemtuzumab (do not administer gemtuzumab in the consolidation cycles).
- PEDIATRICS: Patients should have a platelet count of 75 Gi/L before the next cycle (induction or intensification).
PERSISTENT NEUTROPENIA:
- ADULTS: If the neutrophil count does not recover to greater than 0.5 Gi/L within 14 days following the planned start date of the consolidation cycle (14 days after hematologic recovery following the previous cycle), discontinue gemtuzumab (do not administer gemtuzumab in the consolidation cycles).
- PEDIATRICS: Patients should have a neutrophil count of 1 Gi/L before the next cycle (induction or intensification).
FOR ALL PATIENTS RECEIVING GEMTUZUMAB (MONOTHERAPY OR COMBINATION THERAPY:
VENO-OCCLUSIVE LIVER DISEASE (VOD):
- Manage hepatic toxicity by dose interruption or discontinuation of therapy.
- In patients who experience VOD, discontinue therapy and treatment according to standard medical practice.
INFUSION-RELATED REACTIONS:
- Interrupt the infusion and manage medically.
- Administer acetaminophen, diphenhydramine, and/or methylprednisolone, if needed. Provide supportive care as needed.
- For mild, moderate, or severe infusion-related reactions, once symptoms resolve, consider resuming the infusion at no more than one-half the rate at which the reaction occurred.
- Repeat the procedure in the event of a recurrence of symptoms.
- Permanently discontinue therapy upon the occurrence of a severe infusion reaction or for any life-threatening infusion reaction.
OTHER SEVERE OR LIFE-THREATENING NONHEMATOLOGIC TOXICITIES:
- Delay therapy until recovery to a severity of no more than mild.
- Omit scheduled dose if delayed more than 2 days between sequential infusions.
Administration advice:
- Use an in-line 0.2-micron polyethersulfone (PES) filter for infusion.
- Protect the IV bag from light using a light-blocking cover during the infusion. The infusion line does not need to be protected from light.
- Infuse the diluted solution over 2 hours.
Side Effects
The Most Common
- rash
- diarrhea
- constipation
- nausea
- vomiting
- headache
- pain
- pain, swelling, or sores in mouth or throat
- unusual or severe bleeding or bruising
- cough, shortness of breath, or difficulty breathing
- fast heartbeat
- fever, chills, sore throat, or other signs of infection
More common
- Bleeding gums
- blood in the urine or stools
- blurred vision
- bone pain
- chest pain
- chills
- confusion
- cough
- coughing up blood
- decreased urine output
- difficulty in breathing or swallowing
- dizziness, lightheadedness, or fainting
- dry mouth
- fast or irregular heartbeat
- fever
- flushed, dry skin
- fruit-like breath odor
- headache
- hoarseness
- increased hunger
- increased menstrual flow or vaginal bleeding
- increased thirst
- increased urination
- irregular heartbeat
- loss of appetite
- loss of consciousness
- lower back or side pain
- mood changes
- muscle pain or cramps
- nausea
- nosebleeds
- numbness or tingling in the hands, feet, or lips
- painful or difficult urination
- paralysis
- pinpoint red spots on the skin
- prolonged bleeding from cuts
- rapid, shallow breathing
- rash
- red or black, tarry stools
- red or dark brown urine
- seizures
- sore throat
- stomach pain and bloating
- sweating
- swelling of the face, ankles, or hands
- tightness in the chest
- unexplained weight loss
- unusual bleeding or bruising
- unusual tiredness or weakness
- vomiting
Rare
- Blue lips and fingernails
- coughing that sometimes produces a pink frothy sputum
- difficult, fast, noisy breathing
- fast, pounding, or irregular heartbeat or pulse
- increased sweating
- pale skin
- ulcers, sores, or white spots in the mouth
- Stomach cramps
- watery or bloody diarrhea
Drug Interactions
| DRUG | INTERACTION |
|---|---|
| Abatacept | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Abatacept. |
| Abciximab | The risk or severity of bleeding can be increased when Abciximab is combined with Gemtuzumab ozogamicin. |
| Acenocoumarol | The risk or severity of bleeding can be increased when Acenocoumarol is combined with Gemtuzumab ozogamicin. |
| Acetylsalicylic acid | The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Gemtuzumab ozogamicin. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Gemtuzumab ozogamicin. |
| Adenovirus type | The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Gemtuzumab ozogamicin. |
| Aducanumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Aducanumab. |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Gemtuzumab ozogamicin. |
| Alefacept | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Alefacept. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Alemtuzumab. |
| Alirocumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Alirocumab. |
| Allogeneic | The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Allopurinol | The risk or severity of adverse effects can be increased when Allopurinol is combined with Gemtuzumab ozogamicin. |
| Alteplase | The risk or severity of bleeding can be increased when Alteplase is combined with Gemtuzumab ozogamicin. |
| Altretamine | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Altretamine. |
| Amivantamab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Amivantamab. |
| Amsacrine | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Amsacrine. |
| Anagrelide | The risk or severity of bleeding can be increased when Anagrelide is combined with Gemtuzumab ozogamicin. |
| Anakinra | The risk or severity of adverse effects can be increased when Anakinra is combined with Gemtuzumab ozogamicin. |
| Ancrod | The risk or severity of bleeding can be increased when Ancrod is combined with Gemtuzumab ozogamicin. |
| Anifrolumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Anifrolumab. |
| Anistreplase | The risk or severity of bleeding can be increased when Anistreplase is combined with Gemtuzumab ozogamicin. |
| Ansuvimab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ansuvimab. |
| Anthrax immune | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Anthrax vaccine | The risk or severity of infection can be increased when Anthrax vaccine is combined with Gemtuzumab ozogamicin. |
| Antilymphocyte | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Antilymphocyte immunoglobulin (horse). |
| Antithrombin Alfa | The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Gemtuzumab ozogamicin. |
| Antithrombin | The risk or severity of bleeding can be increased when Antithrombin III human is combined with Gemtuzumab ozogamicin. |
| Antithymocyte | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Antithymocyte immunoglobulin (rabbit). |
| Apixaban | The risk or severity of bleeding can be increased when Apixaban is combined with Gemtuzumab ozogamicin. |
| Apremilast | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Apremilast. |
| Ardeparin | The risk or severity of bleeding can be increased when Ardeparin is combined with Gemtuzumab ozogamicin. |
| Argatroban | The risk or severity of bleeding can be increased when Argatroban is combined with Gemtuzumab ozogamicin. |
| Arsenic trioxide | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Arsenic trioxide. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Articaine. |
| Asfotase alfa | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Asfotase alfa. |
| ACOVID-19 Vaccine | The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Atezolizumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Atezolizumab. |
| Atoltivimab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Atoltivimab. |
| Avelumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Avelumab. |
| Azacitidine | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Azacitidine. |
| Azathioprine | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Azathioprine. |
| Bacillus | The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Gemtuzumab ozogamicin. |
| Bacillus antigen | The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Bacillus calmette | The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Gemtuzumab ozogamicin. |
| Bamlanivimab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bamlanivimab. |
| Baricitinib | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Baricitinib. |
| Basiliximab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Basiliximab. |
| BCG vaccine | The risk or severity of infection can be increased when BCG vaccine is combined with Gemtuzumab ozogamicin. |
| Beclomethasone | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Beclomethasone dipropionate. |
| Belantamab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Belantamab mafodotin. |
| Belatacept | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Belatacept. |
| Belimumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Belimumab. |
| Belinostat | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Belinostat. |
| Belumosudil | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Belumosudil. |
| Bemiparin | The risk or severity of bleeding can be increased when Bemiparin is combined with Gemtuzumab ozogamicin. |
| Bendamustine | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bendamustine. |
| Bendroflumethiazide | The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Gemtuzumab ozogamicin. |
| Benralizumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Benralizumab. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Benzocaine. |
| Benzthiazide | The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Gemtuzumab ozogamicin. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Benzyl alcohol. |
| Besilesomab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Besilesomab. |
| Betamethasone | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Betamethasone. |
| Betrixaban | The risk or severity of bleeding can be increased when Betrixaban is combined with Gemtuzumab ozogamicin. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bevacizumab. |
| Bexarotene | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bexarotene. |
| Bezlotoxumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bezlotoxumab. |
| Bimekizumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bimekizumab. |
| Bivalirudin | The risk or severity of bleeding can be increased when Bivalirudin is combined with Gemtuzumab ozogamicin. |
| Bleomycin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bleomycin. |
| Blinatumomab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Blinatumomab. |
| Bordetella | The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Bortezomib | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bortezomib. |
| Bosutinib | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bosutinib. |
| Brentuximab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Brentuximab vedotin. |
| Brodalumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Brodalumab. |
| Brolucizumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Brolucizumab. |
| Budesonide | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Budesonide. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Bupivacaine. |
| Burosumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Burosumab. |
| Busulfan | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Busulfan. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Butacaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Butamben. |
| Cabazitaxel | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cabazitaxel. |
| Canakinumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Canakinumab. |
| Cangrelor | The risk or severity of bleeding can be increased when Cangrelor is combined with Gemtuzumab ozogamicin. |
| Capecitabine | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Capecitabine. |
| Caplacizumab | The risk or severity of bleeding can be increased when Caplacizumab is combined with Gemtuzumab ozogamicin. |
| Capromab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Capromab pendetide. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Capsaicin. |
| Carbamazepine | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Carbamazepine. |
| Carboplatin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Carboplatin. |
| Carfilzomib | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Carfilzomib. |
| Carmustine | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Carmustine. |
| Casirivimab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Casirivimab. |
| Catumaxomab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Catumaxomab. |
| Cemiplimab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cemiplimab. |
| Certolizumab pegol | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Certolizumab pegol. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Gemtuzumab ozogamicin. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Chlorambucil. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Chloramphenicol. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Chloroprocaine. |
| Chlorothiazide | The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Gemtuzumab ozogamicin. |
| Ciclesonide | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ciclesonide. |
| Cilgavimab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cilgavimab. |
| Cilostazol | The risk or severity of bleeding can be increased when Cilostazol is combined with Gemtuzumab ozogamicin. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Cinchocaine. |
| Cisplatin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cisplatin. |
| Cladribine | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cladribine. |
| Clobetasol | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Clobetasol propionate. |
| Clofarabine | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Clofarabine. |
| Clopidogrel | The risk or severity of bleeding can be increased when Clopidogrel is combined with Gemtuzumab ozogamicin. |
| Clostridium | The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Clozapine | The risk or severity of neutropenia can be increased when Gemtuzumab ozogamicin is combined with Clozapine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Cocaine. |
| Cestrogens | Conjugated estrogens may increase the thrombogenic activities of Gemtuzumab ozogamicin. |
| Corticotropin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Corticotropin. |
| Cortisone acetate | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cortisone acetate. |
| Corynebacterium | The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Cyanocobalamin | The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Cyclopenthiazide | The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Gemtuzumab ozogamicin. |
| Cyclophosphamide | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cyclophosphamide. |
| Cyclosporine | Gemtuzumab ozogamicin may increase the immunosuppressive activities of Cyclosporine. |
| Cyclothiazide | The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Gemtuzumab ozogamicin. |
| Cytarabine | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cytarabine. |
| Dabigatran | The risk or severity of bleeding can be increased when Dabigatran is combined with Gemtuzumab ozogamicin. |
| Dabigatran | The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Gemtuzumab ozogamicin. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dacarbazine. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dactinomycin. |
| Dalteparin | The risk or severity of bleeding can be increased when Dalteparin is combined with Gemtuzumab ozogamicin. |
| Danaparoid | The risk or severity of bleeding can be increased when Danaparoid is combined with Gemtuzumab ozogamicin. |
| Daratumumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Daratumumab. |
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Gemtuzumab ozogamicin. |
| Dasatinib | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dasatinib. |
| Daunorubicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Daunorubicin. |
| Decitabine | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Decitabine. |
| Defibrotide | The risk or severity of bleeding can be increased when Defibrotide is combined with Gemtuzumab ozogamicin. |
| Deflazacort | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Deflazacort. |
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Gemtuzumab ozogamicin. |
| Desirudin | The risk or severity of bleeding can be increased when Desirudin is combined with Gemtuzumab ozogamicin. |
| Desoximetasone | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Desoximetasone. |
| Deucravacitinib | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Deucravacitinib. |
| Dexamethasone | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dexamethasone. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dexrazoxane. |
| Dextran | The risk or severity of bleeding can be increased when Dextran is combined with Gemtuzumab ozogamicin. |
| Dicoumarol | The risk or severity of bleeding can be increased when Dicoumarol is combined with Gemtuzumab ozogamicin. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Gemtuzumab ozogamicin. |
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Gemtuzumab ozogamicin. |
| Difluocortolone | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Difluocortolone. |
| Digoxin Immune | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Digoxin Immune Fab (Ovine). |
| Dimethyl fumarate | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dimethyl fumarate. |
| Dinutuximab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dinutuximab. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Diphenhydramine. |
| Dipyridamole | The risk or severity of bleeding can be increased when Dipyridamole is combined with Gemtuzumab ozogamicin. |
| Diroximel | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Diroximel fumarate. |
| Docetaxel | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Docetaxel. |
| Dostarlimab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dostarlimab. |
| Doxorubicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Doxorubicin. |
| Drotrecogin alfa | The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Gemtuzumab ozogamicin. |
| Dulaglutide | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dulaglutide. |
| Dupilumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dupilumab. |
| Durvalumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Durvalumab. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Dyclonine. |
| Ebola Zaire | The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Eculizumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Eculizumab. |
| Edetic acid | The risk or severity of bleeding can be increased when Edetic acid is combined with Gemtuzumab ozogamicin. |
| Edoxaban | The risk or severity of bleeding can be increased when Edoxaban is combined with Gemtuzumab ozogamicin. |
| Efalizumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Efalizumab. |
| Eflapegrastim | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Eflapegrastim. |
| Eftrenonacog alfa | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Eftrenonacog alfa. |
| Elotuzumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Elotuzumab. |
| Emapalumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Emapalumab. |
| Emicizumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Emicizumab. |
| Enoxaparin | The risk or severity of bleeding can be increased when Enoxaparin is combined with Gemtuzumab ozogamicin. |
| Epirubicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Epirubicin. |
| Epoprostenol | The risk or severity of bleeding can be increased when Epoprostenol is combined with Gemtuzumab ozogamicin. |
| Eptifibatide | The risk or severity of bleeding can be increased when Eptifibatide is combined with Gemtuzumab ozogamicin. |
| Eptinezumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Eptinezumab. |
| Erenumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Erenumab. |
| Eribulin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Eribulin. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Gemtuzumab ozogamicin. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Gemtuzumab ozogamicin. |
| Estetrol | Estetrol may increase the thrombogenic activities of Gemtuzumab ozogamicin. |
| Estradiol | Estradiol may increase the thrombogenic activities of Gemtuzumab ozogamicin. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Gemtuzumab ozogamicin. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Gemtuzumab ozogamicin. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Gemtuzumab ozogamicin. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Gemtuzumab ozogamicin. |
| Estramustine | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Estramustine. |
| Estriol | Estriol may increase the thrombogenic activities of Gemtuzumab ozogamicin. |
| Estrone | Estrone may increase the thrombogenic activities of Gemtuzumab ozogamicin. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Gemtuzumab ozogamicin. |
| Etanercept | The risk or severity of adverse effects can be increased when Etanercept is combined with Gemtuzumab ozogamicin. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Gemtuzumab ozogamicin. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Ethyl chloride. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Etidocaine. |
| Etoposide | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Etoposide. |
| Everolimus | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Everolimus. |
| Evolocumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Evolocumab. |
| Famtozinameran | The therapeutic efficacy of Famtozinameran can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Fanolesomab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fanolesomab. |
| Filgotinib | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Filgotinib. |
| Fingolimod | Gemtuzumab ozogamicin may increase the immunosuppressive activities of Fingolimod. |
| Floxuridine | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Floxuridine. |
| Flucytosine | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Flucytosine. |
| Fludarabine | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fludarabine. |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fludrocortisone. |
| Fluindione | The risk or severity of bleeding can be increased when Fluindione is combined with Gemtuzumab ozogamicin. |
| Flunisolide | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Flunisolide. |
| Fluocinolone | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluocinolone acetonide. |
| Fluocinonide | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluocinonide. |
| Fluocortolone | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluocortolone. |
| Fluorometholone | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluorometholone. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluorouracil. |
| Flupentixol | The risk or severity of myelosuppression can be increased when Flupentixol is combined with Gemtuzumab ozogamicin. |
| Fluprednisolone | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluprednisolone. |
| Fluticasone | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluticasone. |
| Fluticasone furoate | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluticasone furoate. |
| Fluticasone | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluticasone propionate. |
| Fondaparinux | The risk or severity of bleeding can be increased when Fondaparinux is combined with Gemtuzumab ozogamicin. |
| Fremanezumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fremanezumab. |
| Galcanezumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Galcanezumab. |
| Gallium nitrate | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Gallium nitrate. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Gemcitabine. |
| Glatiramer | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Glatiramer. |
| Golimumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Golimumab. |
| Guselkumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Guselkumab. |
| Haemophilus | The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Heparin | The risk or severity of bleeding can be increased when Heparin is combined with Gemtuzumab ozogamicin. |
| Hepatitis A | The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Hepatitis globulin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hepatitis B immune globulin. |
| Hepatitis B Vaccine | The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Human adenovirus | The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Gemtuzumab ozogamicin. |
| Human globulin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Human cytomegalovirus immune globulin. |
| immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Gemtuzumab ozogamicin. |
| immune globulin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Human Rho(D) immune globulin. |
| Human varicella | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Human varicella-zoster immune globulin. |
| Hydrochlorothiazide | The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Gemtuzumab ozogamicin. |
| Hydrocortisone | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hydrocortisone acetate. |
| Hydrocortisone | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hydrocortisone butyrate. |
| Hydrocortisone | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hydrocortisone succinate. |
| Hydroflumethiazide | The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Gemtuzumab ozogamicin. |
| Hydroxychloroquine | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hydroxychloroquine. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hydroxyurea. |
| Ibalizumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ibalizumab. |
| Ibritumomab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ibritumomab tiuxetan. |
| Ibrutinib | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ibrutinib. |
| Icosapent ethyl | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Gemtuzumab ozogamicin. |
| Idarubicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Idarubicin. |
| Idarucizumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Idarucizumab. |
| Idelalisib | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Idelalisib. |
| Ifosfamide | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ifosfamide. |
| Iloprost | The risk or severity of bleeding can be increased when Iloprost is combined with Gemtuzumab ozogamicin. |
| Imatinib | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Imatinib. |
| Imdevimab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Imdevimab. |
| Imlifidase | The therapeutic efficacy of Gemtuzumab ozogamicin can be decreased when used in combination with Imlifidase. |
| Indomethacin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Indomethacin. |
| Inebilizumab | The risk or severity of infection can be increased when Gemtuzumab ozogamicin is combined with Inebilizumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Infliximab. |
| Influenza A | The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Influenza A virus | The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Influenza | The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Influenza A virus | The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Influenza A virus A | The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Influenza A | The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Influenza A | The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Influenza A virus | The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Influenza A | The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Influenza B | The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Influenza B | The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Influenza B | The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Influenza B | The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Inotuzumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Inotuzumab ozogamicin. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Gemtuzumab ozogamicin. |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Interferon alfa-2b. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Gemtuzumab ozogamicin. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Gemtuzumab ozogamicin. |
| Interferon | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Interferon alfacon-1. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Interferon beta-1b. |
| Interferon gamm | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Gemtuzumab ozogamicin. |
| Ipilimumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ipilimumab. |
| Irinotecan | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Irinotecan. |
| Isatuximab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Isatuximab. |
| Ixabepilone | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ixabepilone. |
| Ixekizumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ixekizumab. |
| COVID-19 Vaccine | The therapeutic efficacy of Janssen COVID-19 Vaccine can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Ja encephalitis | The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Lanadelumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lanadelumab. |
| Leflunomide | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Leflunomide. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lenalidomide. |
| Lepirudin | The risk or severity of bleeding can be increased when Lepirudin is combined with Gemtuzumab ozogamicin. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Levobupivacaine. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Lidocaine. |
| Linezolid | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Linezolid. |
| Lipegfilgrastim | Gemtuzumab ozogamicin may increase the myelosuppressive activities of Lipegfilgrastim. |
| Lomustine | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lomustine. |
| Loncastuximab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Loncastuximab tesirine. |
| Lopinavir | The serum concentration of Gemtuzumab ozogamicin can be increased when it is combined with Lopinavir. |
| Maftivimab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Maftivimab. |
| Magnesium | The serum concentration of Magnesium can be decreased when it is combined with Gemtuzumab ozogamicin. |
| Margetuximab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Margetuximab. |
| Measles virus | The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Mechlorethamine | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mechlorethamine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Meloxicam. |
| Melphalan | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Melphalan. |
| Meningococcal | The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Mepivacaine. |
| Mepolizumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mepolizumab. |
| Meprednisone | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Meprednisone. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mercaptopurine. |
| Mestranol | Mestranol may increase the thrombogenic activities of Gemtuzumab ozogamicin. |
| Methimazole | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Methimazole. |
| Methotrexate | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Methotrexate. |
| Methoxy | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Gemtuzumab ozogamicin. |
| Methylprednisolone | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Methylprednisolone. |
| Mirvetuximab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mirvetuximab Soravtansine. |
| Mitomycin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mitomycin. |
| Mitoxantrone | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mitoxantrone. |
| COVID-19 Vaccine | The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Modified v | The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Mogamulizumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mogamulizumab. |
| Mometasone | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mometasone furoate. |
| Monomethyl | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Monomethyl fumarate. |
| Mosunetuzumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mosunetuzumab. |
| Mumps virus n | The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Muromonab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Muromonab. |
| Mycophenolate | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mycophenolate mofetil. |
| Mycophenolic | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mycophenolic acid. |
| Nadroparin | The risk or severity of bleeding can be increased when Nadroparin is combined with Gemtuzumab ozogamicin. |
| Natalizumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Natalizumab. |
| Necitumumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Necitumumab. |
| Nelarabine | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Nelarabine. |
| Nilotinib | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Nilotinib. |
| Nimesulide | The risk or severity of bleeding can be increased when Nimesulide is combined with Gemtuzumab ozogamicin. |
| Nivolumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Nivolumab. |
| Nuvaxovid | The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Obiltoxaximab. |
| Obinutuzumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Obinutuzumab. |
| Ocrelizumab | Ocrelizumab may increase the immunosuppressive activities of Gemtuzumab ozogamicin. |
| Odesivimab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Odesivimab. |
| Ofatumumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ofatumumab. |
| Olaparib | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Olaparib. |
| Olaratumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Olaratumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Gemtuzumab ozogamicin. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Oxaliplatin. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Oxetacaine. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Oxybuprocaine. |
| Ozanimod | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ozanimod. |
| Paclitaxel | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Paclitaxel. |
| Palbociclib | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Palbociclib. |
| Palifermin | The therapeutic efficacy of Palifermin can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Palivizumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Palivizumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Panitumumab. |
| Panobinostat | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Panobinostat. |
| Parnaparin | The risk or severity of bleeding can be increased when Parnaparin is combined with Gemtuzumab ozogamicin. |
| Pazopanib | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pazopanib. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pegaspargase. |
| Pegcetacoplan | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pegcetacoplan. |
| Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Gemtuzumab ozogamicin. |
| Peginterferon | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Gemtuzumab ozogamicin. |
| Peginterferon 2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Gemtuzumab ozogamicin. |
| Peginterferon | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Peginterferon beta-1a. |
| Pembrolizumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pembrolizumab. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pemetrexed. |
| Penicillamine | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Penicillamine. |
| Pentosan p | The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Gemtuzumab ozogamicin. |
| Pentostatin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pentostatin. |
| Pentoxifylline | The risk or severity of bleeding can be increased when Pentoxifylline is combined with Gemtuzumab ozogamicin. |
| Pertussis vaccine | The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Pertuzumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pertuzumab. |
| Pexidartinib | Gemtuzumab ozogamicin may increase the hepatotoxic activities of Pexidartinib. |
| Phenindione | The risk or severity of bleeding can be increased when Phenindione is combined with Gemtuzumab ozogamicin. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Phenol. |
| Phenprocoumon | The risk or severity of bleeding can be increased when Phenprocoumon is combined with Gemtuzumab ozogamicin. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Phenylalanine. |
| Pimecrolimus | The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Gemtuzumab ozogamicin. |
| Pirfenidone | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pirfenidone. |
| Polatuzumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Polatuzumab vedotin. |
| Polyestradiol | Polyestradiol phosphate may increase the thrombogenic activities of Gemtuzumab ozogamicin. |
| Polythiazide | The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Gemtuzumab ozogamicin. |
| Pomalidomide | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pomalidomide. |
| Ponatinib | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ponatinib. |
| Ponesimod | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ponesimod. |
| Pralatrexate | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pralatrexate. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Pramocaine. |
| Prasugrel | The risk or severity of bleeding can be increased when Prasugrel is combined with Gemtuzumab ozogamicin. |
| Prednisolone | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Prednisolone. |
| Prednisone | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Prednisone. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Prilocaine. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Procaine. |
| Procarbazine | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Procarbazine. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Proparacaine. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Propoxycaine. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Propylthiouracil. |
| Protein C | The risk or severity of bleeding can be increased when Protein C is combined with Gemtuzumab ozogamicin. |
| Protein S | The risk or severity of bleeding can be increased when Protein S human is combined with Gemtuzumab ozogamicin. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Gemtuzumab ozogamicin. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ramucirumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ranibizumab. |
| Ravulizumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ravulizumab. |
| Raxibacumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Raxibacumab. |
| Reslizumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Reslizumab. |
| Reteplase | The risk or severity of bleeding can be increased when Reteplase is combined with Gemtuzumab ozogamicin. |
| Reviparin | The risk or severity of bleeding can be increased when Reviparin is combined with Gemtuzumab ozogamicin. |
| Rilonacept | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Rilonacept. |
| Risankizumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Risankizumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Rituximab. |
| Rivaroxaban | The risk or severity of bleeding can be increased when Rivaroxaban is combined with Gemtuzumab ozogamicin. |
| Roflumilast | Roflumilast may increase the immunosuppressive activities of Gemtuzumab ozogamicin. |
| Romosozumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Romosozumab. |
| Ropeginterferon | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ropeginterferon alfa-2b. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Ropivacaine. |
| Rotavirus vaccine | The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Rubella virus vaccine | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Gemtuzumab ozogamicin. |
| Ruxolitinib | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ruxolitinib. |
| Sacituzumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sacituzumab govitecan. |
| Sarilumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sarilumab. |
| Satralizumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Satralizumab. |
| Secukinumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Secukinumab. |
| Siltuximab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Siltuximab. |
| Siponimod | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Siponimod. |
| Sipuleucel-T | The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Sirolimus | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sirolimus. |
| Smallpox | The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Sodium citrate | The risk or severity of bleeding can be increased when Sodium citrate is combined with Gemtuzumab ozogamicin. |
| Sorafenib | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sorafenib. |
| Sotrovimab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sotrovimab. |
| Spesolimab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Spesolimab. |
| Streptokinase | The risk or severity of bleeding can be increased when Streptokinase is combined with Gemtuzumab ozogamicin. |
| Streptozocin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Streptozocin. |
| Sulesomab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sulesomab. |
| Sulfamethoxazole | The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Gemtuzumab ozogamicin. |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sulfasalazine. |
| Sulfinpyrazone | The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Gemtuzumab ozogamicin. |
| Sulodexide | The risk or severity of bleeding can be increased when Sulodexide is combined with Gemtuzumab ozogamicin. |
| Sunitinib | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sunitinib. |
| Sutimlimab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sutimlimab. |
| SyEstrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Gemtuzumab ozogamicin. |
| SEstrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Gemtuzumab ozogamicin. |
| Tacrolimus | Tacrolimus may increase the immunosuppressive activities of Gemtuzumab ozogamicin. |
| Tafasitamab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tafasitamab. |
| Tedizolid | The risk or severity of myelosuppression can be increased when Gemtuzumab ozogamicin is combined with Tedizolid phosphate. |
| Temozolomide | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Temozolomide. |
| Temsirolimus | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Temsirolimus. |
| Tenecteplase | The risk or severity of bleeding can be increased when Tenecteplase is combined with Gemtuzumab ozogamicin. |
| Teniposide | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Teniposide. |
| Teplizumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Teplizumab. |
| Teprotumumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Teprotumumab. |
| Teriflunomide | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Teriflunomide. |
| Tetanus | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tetanus immune globulin, human. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Tetracaine. |
| Tezepelumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tezepelumab. |
| Thalidomide | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Thalidomide. |
| Thiotepa | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Thiotepa. |
| Tibolone | Tibolone may increase the thrombogenic activities of Gemtuzumab ozogamicin. |
| Ticagrelor | The risk or severity of bleeding can be increased when Ticagrelor is combined with Gemtuzumab ozogamicin. |
| Tick-borne | The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Ticlopidine | The risk or severity of bleeding can be increased when Ticlopidine is combined with Gemtuzumab ozogamicin. |
| Tildrakizumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tildrakizumab. |
| Tinzaparin | The risk or severity of bleeding can be increased when Tinzaparin is combined with Gemtuzumab ozogamicin. |
| Tioguanine | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tioguanine. |
| Tirofiban | The risk or severity of bleeding can be increased when Tirofiban is combined with Gemtuzumab ozogamicin. |
| Tisotumab vedotin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tisotumab vedotin. |
| Tixagevimab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tixagevimab. |
| Tixocortol | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tixocortol. |
| Tocilizumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tocilizumab. |
| Tofacitinib | Gemtuzumab ozogamicin may increase the immunosuppressive activities of Tofacitinib. |
| Topotecan | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Topotecan. |
| Tositumomab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tositumomab. |
| Trabectedin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Trabectedin. |
| Tralokinumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tralokinumab. |
| Trastuzumab | Trastuzumab may increase the neutropenic activities of Gemtuzumab ozogamicin. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Trastuzumab deruxtecan. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Trastuzumab emtansine. |
| Tremelimumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tremelimumab. |
| Tretinoin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tretinoin. |
| Triamcinolone | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Triamcinolone. |
| Trichlormethiazide | The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Gemtuzumab ozogamicin. |
| Trifluridine | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Trifluridine. |
| Triflusal | The risk or severity of bleeding can be increased when Triflusal is combined with Gemtuzumab ozogamicin. |
| Trilostane | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Trilostane. |
| Typhoid vaccine | The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Typhoid Vaccine | The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Gemtuzumab ozogamicin. |
| Typhoid | The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Upadacitinib | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Upadacitinib. |
| Urokinase | The risk or severity of bleeding can be increased when Urokinase is combined with Gemtuzumab ozogamicin. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ustekinumab. |
| Valoctocogene | The therapeutic efficacy of Valoctocogene roxaparvovec can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Varicella zoster | The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Gemtuzumab ozogamicin. |
| Varicella zoster | The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Vedolizumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vedolizumab. |
| Vibrio cholerae | The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Vilanterol | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vilanterol. |
| Vinblastine | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vinblastine. |
| Vincristine | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vincristine. |
| Vindesine | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vindesine. |
| Vinorelbine | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vinorelbine. |
| Voclosporin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Voclosporin. |
| Vorapaxar | The risk or severity of bleeding can be increased when Vorapaxar is combined with Gemtuzumab ozogamicin. |
| Vorinostat | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vorinostat. |
| Warfarin | The risk or severity of bleeding can be increased when Warfarin is combined with Gemtuzumab ozogamicin. |
| Ximelagatran | The risk or severity of bleeding can be increased when Ximelagatran is combined with Gemtuzumab ozogamicin. |
| Yellow fever | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Gemtuzumab ozogamicin. |
| Zidovudine | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Zidovudine. |
Pregnancy and Lactation
US FDA pregnancy category Not Assigned
Pregnancy
Based on its mechanism of action and findings from animal studies [see Clinical Pharmacology (12.1) and Nonclinical Toxicology (13.1)], MYLOTARG can cause embryo-fetal harm when administered to a pregnant woman. There are no available data on MYLOTARG use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. In rat embryo-fetal development studies, gemtuzumab ozogamicin caused embryo-fetal toxicity at maternal systemic exposures that were greater than or equal to 0.4 times the
exposure in patients at the maximum recommended dose, based on AUC (see Data). If MYLOTARG is used during pregnancy, or if the patient becomes pregnant while taking MYLOTARG, advise the patient of the potential risk to a fetus.
Lactation
There are no data on the presence of gemtuzumab ozogamicin or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production. Because of the potential for adverse reactions in breastfed infants, women should not breastfeed during treatment with MYLOTARG and for at least 1 month after the final dose.
How should this medicine be used?
Gemtuzumab ozogamicin injection comes as a powder to be mixed with liquid and given through a needle or catheter placed into a vein. It is usually injected slowly over a period of 2 hours. Your doctor will tell you how often you will receive gemtuzumab ozogamicin injection. The dosing schedule depends on if you are being treated with other chemotherapy medications, if your cancer was previously treated, and how your body responds to the medication.
Gemtuzumab ozogamicin injection may cause serious or life-threatening reactions during an infusion and for up to a day afterwards. You will receive certain medications to help prevent a reaction before you receive each dose of gemtuzumab ozogamicin. A doctor or nurse will watch you closely while you are receiving the infusion and shortly after the infusion to be sure you are not having a serious reaction to the medication. Tell your doctor or nurse immediately if you experience any of the following symptoms that may occur during or within 24 hours after the infusion: rash, fever, chills, fast heartbeat, swollen tongue or throat, shortness of breath or difficulty breathing.
Your doctor may slow down your infusion, delay, or stop your treatment with gemtuzumab ozogamicin injection, or treat you with additional medications depending on your response to the medication and any side effects that you experience. Talk to your doctor about how you are feeling during and after your treatment.
What special precautions should I follow?
Before receiving gemtuzumab ozogamicin injection,
- tell your doctor and pharmacist if you are allergic to gemtuzumab ozogamicin, any other medications, or any of the ingredients in gemtuzumab ozogamicin injection. Ask your pharmacist for a list of the ingredients.
- tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: amiodarone (Cordarone, Nexterone, Pacerone), anagrelide (Agrylin), chloroquine, chlorpromazine, cilostazol, citalopram (Celexa), disopyramide (Norpace), dofetilide (Tikosyn), donepezil (Aricept, in Namzaric), dronedarone (Multaq), escitalopram (Lexapro), flecainide (Tambocor), fluconazole (Diflucan), haloperidol (Haldol), ibutilide (Corvert), methadone (Methadose, Dolophine), ondansetron (Zuplenz, Sofran), pimozide (Orap), procainamide, quinidine (in Nuedexta), sotalol (Betapace, Sorine, Sotylize), and thioridazine. Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with gemtuzumab ozogamicin injection, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
- tell your doctor if you or anyone in your family has or has ever had long QT syndrome (condition that increases the risk of developing an irregular heartbeat that may cause fainting or sudden death), or if you have or have ever had or higher or lower than normal levels of sodium, potassium, calcium, or magnesium in your blood.
- tell your doctor if you are pregnant, plan to become pregnant, or plan to father a child. You should not become pregnant while you are receiving gemtuzumab ozogamicin injection. You will need to have a negative pregnancy test before you begin receiving this medication. Use effective birth control during your treatment with gemtuzumab ozogamicin injection and for 6 months after your final dose. If you are a male and your partner can become pregnant, you should use effective birth control during your treatment and for 3 months after your final dose. If you or your partner become pregnant while receiving gemtuzumab ozogamicin injection, call your doctor.
- tell your doctor if you are breastfeeding. You should not breastfeed while you are receiving gemtuzumab ozogamicin injection, and for 1 month after your final dose.
- you should know that this medication may decrease fertility in men and women. Talk to your doctor about the risks of receiving gemtuzumab ozogamicin.
References
Shop From Rxharun..
About Us...
Editorial Board Members..
Developers Team...
Team Rxharun.